Last update June 7, 2022
Very High Risk
An immunosuppressant with antiproliferative properties used as a disease-modifying antirheumatic drug (DMARD) in rheumatoid arthritis, psoriatic arthritis and in some neoplasms. Its main active metabolite is teriflunomide. Oral administration once or twice a day for months.
Since the last update we have not found published data on its excretion in breastmilk.
Its high binding to plasma proteins makes its transfer to milk in significant concentrations unlikely.
Its slow elimination (half-life of 15 days) and its potentially serious side effects means it is recommended that, until there is more published data on this drug in relation to breastfeeding, safer alternatives are used (Sammaritano 2020, Götestam 2016, Flint 2016, Sammaritano 2014, Weber 2008, Østensen 2006, Temprano 2005), especially during the neonatal period and in case of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM